Retinal Vein Occlusion (RVO) Treatment Market Size

Retinal Vein Occlusion Treatment Market Size

Retinal Vein Occlusion Treatment Market size was valued at USD 2.2 billion in 2023 and is estimated to grow at 5.8% CAGR from 2024 to 2032. RVO is among the most common retinal vascular diseases. The market has seen considerable growth due to the rising prevalence of diabetes and hypertension, a key risk factors of RVO driving demand for effective treatments.

According to the World Health Organization (WHO), around 1.28 billion adults aged 30-79 worldwide suffer from hypertension, with two-thirds living in middle- and low-income countries. Hypertension can cause occlusion of major retinal vessels, such as the central and branch retinal veins, leading to vascular occlusion and vision loss. As a result, the increasing incidence of these hypertension-related complications is expected to drive the prevalence of RVO, thereby supporting market growth. Moreover, advancements in diagnostic technologies and therapeutic options including ophthalmology drugs such as anti-VEGF drugs and corticosteroid implants are improving patient outcomes and fueling market expansion.
 

Retinal vein occlusion (RVO) is a common retinal vascular disorder characterized by the blockage of the retinal veins, leading to impaired blood flow and potential vision loss. It occurs when a blood clot forms in the retinal vein, resulting in swelling, hemorrhage, and ischemia within the retina. RVO is primarily classified into two types that include central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), depending on the location of the blockage.